Assessing the Value of a Dosage of Anti-cetuximab in the Therapeutic Management of Patients With Colon Cancer or Upper Aero-digestive Tract and Candidates for Treatment With Cetuximab

Assessing the Value of a Dosage of Anti-cetuximab in the Therapeutic Management of Patients With Colon Cancer or Upper Aero-digestive Tract and Candidates for Treatment With Cetuximab

The main objective of this study is to validate the utility of IgE anti-cetuximab in the treatment strategy to identify patients at risk for a severe allergic reaction to cetuximab (grade 3 or 4 of the classification of NCI) and thus reduce the incidence of severe reactions.

Inclusion Criteria:

• Patient informed consent,
• Patient aged over 18 years
• Patients with a WHO performance status ≤ 2,
• Colon cancer or upper aero-digestive tract cytologically or histologically proven
• Patients with an indication to the theoretical use of cetuximab for colon neoplasia or upper aero-digestive tract,
• Haematological and biochemical compatible with combination therapy with cetuximab.

Exclusion Criteria:

• Patients previously treated with cetuximab,
• A person deprived of liberty or under supervision.